

JUL-12-2004 MON 10:25 AM THORPE NORTH WESTERN

FAX NO. 566 6673

OFFICIAL

PATENT APPLICATION  
ATTORNEY DOCKET NO. 22398

IN THE UNITED STATES PATENT & TRADEMARKS OFFICE

RECEIVED  
CENTRAL FAX CENTER

ART UNIT: 3700 3600

EXAMINER: Tejash Patel

APPLICANT: Dane J. Dickson

SERIAL NO.: 10/703,866 10/763,066

FILED: 1/21/2004

CONFIRM. NO.:


FOR: SYSTEMS AND METHODS FOR  
SUCCINCTLY PRESENTING CLINICAL  
TRIAL INFORMATION

JUL 12 2004

CERTIFICATE OF MAILING  
UNDER 37 C.F.R. § 1.8

DATE OF DEPOSIT: 5/7/04

I hereby certify that this paper or fee (along with any paper or fee referred to as being attached or enclosed) is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Gary P. Oakeson

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir/Madam:

Please find, pursuant to 37 C.F.R. § 1.98(a)(1), the enclosed Form PTO-1449 which contains a list of all patents, publications, or other items that have come to the attention of one or more of the individuals designated in 37 C.F.R. § 1.56(c). Applicant respectfully submits that this Information Disclosure Statement is filed pursuant to:

- 37 C.F.R. § 1.97 (b)(1) or (3), within three months of the filing date of the application, or before a first office action on the merits, whichever occurs last;
- 37 C.F.R. § 1.97 (c), after a first office action on the merits, but before a Final Office Action or a Notice of Allowance, whichever occurs first, and is accompanied by either 1) a statement in accordance with 37 C.F.R. § 1.97(e), or 2) the fee set forth in § 1.17(p); or
- 37 C.F.R. § 1.97 (d), after a Final Office Action or Notice of Allowance, whichever occurs first, but on or before payment of the issue fee, and is accompanied by both 1) a statement in accordance with 37 C.F.R. § 1.97(e), and 2) the fee set forth in § 1.17(p).

While no representation is made that any of these references may be "prior art" within the meaning of that term in accordance with 35 U.S.C. §§ 102 or 103, the enclosed list of references is disclosed so as to comply with the duty of disclosure set forth in 37 C.F.R. § 1.56.

Moreover, while no representation is made that a specific search of office files or patent office records has been conducted or that no better art exists, the undersigned attorney of record believes that

Information Disclosure Statement  
Application No. 10/703,066 10743,066  
Page 2

the references listed, together with any other references which may have been previously submitted or listed, are the closest to the claimed invention (taken in its entirety) of which the undersigned is presently aware, and no art which is closer to the claimed invention (taken in its entirety) has been knowingly withheld.

In accordance with 37 C.F.R. §§ 1.97 and 1.98, a copy of each listed reference (or relevant portion thereof) which was not previously submitted to, or cited by, the Patent Office is also enclosed.

Legible copies of the listed non-patent literature and foreign documents or their relevant portions. Copies of U.S. patents and/or publications are NOT included pursuant to the Official Gazette Notice, dated Aug. 5, 2003, waiving the requirement of 37 C.F.R. 1.98(a)(2)(i).


The references listed in the accompanying Form PTO-1449 are NOT enclosed because, under 37 C.F.R. § 1.98(d), they were previously cited by or submitted to the Office in application number \_\_\_\_\_, which is relied upon for an earlier filing date under 35 U.S.C. § 120.

For all listed references that are not either in the English language, or accompanied by a translation into English, a concise explanation of relevance as required under 37 C.F.R. § 1.98(a)(3) is enclosed attached to each.

The Commissioner is hereby authorized to charge any additional fees associated with this communication or to credit any overpayment to Deposit Account No. 20-0100.

Dated this 7<sup>th</sup> day of May, 2004.

Respectfully submitted,

  
Gary P. Oakeson  
Attorney for Applicant  
Registration No. 44,266

THORPE NORTH & WESTERN, LLP  
Customer No. 20,551  
P.O. Box 1219  
Sandy, Utah 84091-1219  
Telephone: (801) 566-6633

  
MWV/JRJ/GPO:ja

Enclosure

H:\FILES\22000\22398\22398 stmt TDS..doc

Sheet 1 of 1

PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 22398	SERIAL NO. 10/703,666 10/763,666
LIST OF PRIOR ART CITED BY APPLICANT		APPLICANT Dane J. Dickson	
		FILING DATE Jan. 21, 2004	GROUP 9700-3600

## U.S. PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A1						
A2						
A3						
A4						
A5						
A6						
A7						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
A8						
A9						
A10						
A11						
A12						

## OTHER PRIOR ART (Including Author, Title, Pertinent Pages, Etc.)

A13	Poster: "Randomized Trial of Tamoxifen Alone . . . Cancer Treatment Group Study," by James N. Ingle, et al., published in the year 2000.
A14	Poster: "A Phase II Trial of 7 Days . . . North Central Cancer Treatment Group Study," by R.M. Goldbeg, et al., published in the year 2000.
A15	Poster: "Percutaneous Administration of . . . of Intrahepatic Lesions of Hepatocellular Carcinoma (HCC)," by Phillip J. Johnson, et al., published in the year 2000.
A16	Poster: "Rituximab Following High Dose . . . of a Phase I-II Trial," by S. Horwitz, et al., published in the year 2000.

EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.